ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Bioinformatics analysis reveals CTSF suppresses tumor cell malignant phenotype and CD8 + T cell exhaustion by downregulating Bcl- 2 protein in the microenvironment of bladder cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting lysosome-dependent cell death in cancer: towards therapeutic strategies.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays an important role in tumor progression. However, the underlying mechanism of TME on bladder cancer (BLCA) progression remains largely unknown. Here, we obtained the BLCA-related gene expression motifs and the fraction of immune cells in TME of BLCA from GSE166947 dataset and TCGA database. Overlapping differentially expressed genes (DEGs) were screened, and the Spearman correlation coefficient between DEGs and the fraction of CD8 + T cell infiltration was calculated. Cathepsin F (CTSF) was screened as a key regulator of tumor cell malignant proliferation and CD8 + T cell infiltration in TME of BLCA. Moreover, CTSF was downregulated in BLCA tissues and cells. BLCA cells were transfected with CTSF shRNA (sh-CTSF) or CTSF lentiviral vector (LV-CTSF), and the supernatants were isolated as conditioned medium (CM) to culture CD8 + T cells. The results showed that overexpression of CTSF inhibited proliferation and induced apoptosis of BLCA cells, silencing CTSF decreased the levels of Granzyme B, TNF-α, IFN-γ, IL-2, and increased the percentage of PD-1 + Tim3 + CD8 + cells. Next, the interaction between CTSF and B-cell lymphoma-2 (Bcl-2) was predicted by STRING and verified by Co-IP analysis. Silencing Bcl-2 reversed CD8 + T cell exhaustion; overexpression of Bcl-2 counteracted CTSF-induced apoptosis of BLCA cells. Finally, T24 cells transfected with recombinant protein (rh-CTSF) were subcutaneously injected into mice to construct xenograft tumor models, and found that overexpression of CTSF inhibited BLCA tumor growth in vivo. In conclusion, CTSF inhibited CD8 + T cell exhaustion and tumor cell malignant proliferation by downregulating Bcl-2 protein level, thus inhibiting the progression of BLCA.
Indexed as
Identifiers
40278892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.